Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Stocks
Currencies
Cryptocurrencies
Metals
Indices
Commodities
ETFs
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
News
Top Providers News
Top Providers News
Symbols
Market
Provider
Time
Symbols
News
Provider
2026.11.05
Ingredion Lowers FY2026 GAAP EPS Guidance from $9.15-$9.75 to $8.04-$8.49 vs $9.60 Est
Benzinga
2026.11.05
Deutsche Bank Upgrades JetBlue Airways to Buy, Raises Price Target to $5.5
Benzinga
2026.11.05
MidCap Financial Q2 EPS $0.34 Misses $0.35 Estimate, Sales $61.982M Miss $64.700M Estimate
Benzinga
2026.11.05
Haemonetics Raises FY2027 Sales Guidance from $1.401B-$1.441B to $1.441B-$1.481B vs $1.418B Est
Benzinga
2026.11.05
BTIG Reiterates Buy on Caris Life Sciences, Maintains $38 Price Target
Benzinga
2026.11.05
Northwest Natural Hldg Raises FY2026 Adj EPS Guidance from $2.95-$3.15 to $3.10-$3.20 vs $3.08 Est
Benzinga
2026.11.05
Ingredion Q3 Adj. EPS $2.28 Misses $2.60 Estimate, Sales $1.792B Miss $1.802B Estimate
Benzinga
2026.11.05
Deutsche Bank Upgrades Frontier Group Holdings to Buy, Raises Price Target to $10
Benzinga
2026.11.05
Lemonade Raises FY2026 Sales Guidance from $1.214B-$1.220B to $1.231B-$1.235B vs $1.218B Est
Benzinga
2026.11.05
LifeStance Health Gr Sees Q4 Sales $446.000M-$466.000M vs $438.561M Est
Benzinga
2026.11.05
LifeStance Health Gr Raises FY2026 Sales Guidance from $1.685B-$1.725B to $1.741B-$1.761B vs $1.709B Est
Benzinga
2026.11.05
ACI Worldwide Affirms FY2026 Sales Guidance of $1.895B-$1.925B vs $1.907B Est
Benzinga
2026.11.05
ACI Worldwide Sees Q4 Sales $612.000M-$642.000M vs $628.404M Est
Benzinga
2026.11.05
Lemonade Sees Q4 Sales $342.000M-$346.000M vs $341.084M Est
Benzinga
2026.11.05
Millicom Q3 GAAP EPS $0.58 vs $1.16 YoY; Prior Year Included $138M Gain On Sale Of Lati Operations
Benzinga
2026.11.05
GigaCloud Tech Sees Q4 Sales $425.000M-$450.000M vs $405.990M Est
Benzinga
2026.11.05
Perimeter Solutions Q3 Adj. EPS $0.85 Misses $0.96 Estimate, Sales $389.865M Beat $381.287M Estimate
Benzinga
2026.11.05
LifeStance Health Gr Q3 EPS $0.06 Beats $0.04 Estimate, Sales $455.900M Beat $431.816M Estimate
Benzinga
2026.11.05
Haemonetics Q2 Adj. EPS $1.35 Beats $1.29 Estimate, Sales $357.759M Beat $345.003M Estimate
Benzinga
2026.11.05
EPAM Systems Sees Q4 GAAP EPS $2.43-$2.51 vs $2.50 Est
Benzinga
2026.11.05
Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate
Benzinga
2026.11.05
EPAM Systems Sees Q4 Adj EPS $3.50-$3.58 vs $3.52 Est; Sees Sales $1.405B-$1.420B vs $1.423B Est
Benzinga
2026.11.05
BeOne Medicines Raises FY2026 Sales Guidance from $6.600B-$6.800B to $6.900B-$7.000B vs $6.763B Est
Benzinga
2026.11.05
Prestige Consumer Lowers FY2027 Adj EPS Guidance from $4.55-$4.65 to $4.48-$4.55 vs $4.58 Est; Lowers FY2027 Sales Guidance from $1.290B-$1.315B to $1.280B-$1.290B vs $1.298B Est
Benzinga
2026.11.05
Carlyle Group Q3 Adj. EPS $1.12 Beats $1.00 Estimate, Sales $994.500M Beat $946.491M Estimate
Benzinga
2026.11.05
Enovis Q3 Adj. EPS $0.88 Beats $0.77 Estimate, Sales $558.725M Beat $557.010M Estimate
Benzinga
2026.11.05
Lincoln National Q3 Adj. EPS $1.72 Misses $1.96 Estimate, Sales $5.481B Beat $4.955B Estimate
Benzinga
2026.11.05
Lamar Advertising Q3 EPS $1.59 Misses $1.67 Estimate, Sales $624.468M Beat $621.864M Estimate
Benzinga
2026.11.05
EPAM Systems Raises FY2026 GAAP EPS Guidance from $8.22-$8.38 to $8.41-$8.49 vs $8.34 Est
Benzinga
2026.11.05
Oscar Health Raises FY2026 Sales Guidance from $18.700B-$19.000B to $19.000B-$19.300B vs $18.732B Est
Benzinga
1
...
241
242
243
244
245
246
...
712
>